Result of AGM
16 December, 2009
Issue of Options
04 December, 2009
Holdings in Company
24 November, 2009
Availability of Report & Accounts
20 November, 2009
Total Voting Rights
30 October, 2009
Final Results
27 October, 2009
Holding(s) in Company
19 October, 2009
NOMAD - Change of Name
19 October, 2009
Holding(s) in Company
15 October, 2009
Issue of Equity
12 October, 2009
Issue of Equity
12 October, 2009
Holding(s) in Company
09 October, 2009
Cancer Research Programme to be Presented
06 October, 2009
Total Voting Rights
30 September, 2009
Holding(s) in Company
21 September, 2009
Holding(s) in Company
16 September, 2009
Holding(s) in Company
10 September, 2009
Issue of Equity
08 September, 2009
Holdings in Company
03 September, 2009
Statement regarding share price movement
28 August, 2009
Statement re. Bulletin Board speculation
05 June, 2009
Holding(s) in Company
24 April, 2009
Holding(s) in Company
20 April, 2009
Holding(s) in Company
23 March, 2009
Statement re Share Price Movement
23 March, 2009
Half Yearly Report
23 February, 2009
Holding(s) in Company
13 February, 2009
Result of AGM
27 January, 2009
Change of registered office
13 January, 2009
Previous releases
2010 2009 2008 2007 2006 2005 2004
News feed
requires RSS news reader
|
|
20 November 2009 |
SAREUM HOLDINGS PLC
("Sareum or the "Company)
Availability of Report & Accounts
The Company announces that the report and accounts for the year ended 30 June 2009 has now been posted to shareholders and is available from the Company’s website www.sareum.co.uk.
|
Sareum Holdings plc |
|
|
Tim Mitchell |
01223 497 700 |
|
|
|
|
Merchant John East Securities Limited (Nominated Adviser) |
|
|
Simon Clements/Bidhi Bhoma |
020 7628 2200 |
|
|
|
|
Hybridan LLP (Broker) |
|
|
Claire Noyce/Stephen Austin |
020 3159 5085 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer.
Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR. For further information, please visit www.sareum.co.uk
Requires MS Word
Requires Adobe Acrobat Reader